To achieve high performance, biopharmaceutical companies will need to develop distinctive—or significantly improved—capabilities in strategic deal making, competitive positioning, analytics, and digital and multichannel interfaces. Accenture works with clients (including all 10 of the top 10 global biopharmaceutical companies) to drive bold growth by differentiating in targeted areas, expanding into adjacent sectors, striking the right partnerships and transforming business models to ultimately reduce costs and improve customer interactions.
Featured Content
 |
Achieving High Performance in the Biopharmaceutical Industry
How Will You Dominate the Game?
The pharmaceutical industry has changed—scale and diversified portfolios no longer guarantee high performance for companies. A powerful mix of long-anticipated forces—healthcare reform, the expiration of major patents and rapid adoption of generics, among others—has changed the game for large biopharmaceuticals. This research report analyzes 16 of the largest biopharmaceutical companies in the world and identifies the key attributes that enabled the high performers to outpace their peers. The piece lays out an approach for companies to dominate the market in the future and the distinctive capabilities they need to do so. |
 |
mHealth: Defining a Role for Biopharmaceutical Companies
Mobile health care has gained significant traction and investment from many participants, as pilots and trials evolve to substantively funded business ventures aimed at reaching broad consumer segments. This whitepaper provides examples and options to help biopharmaceutical companies begin developing or refine mHealth strategies and tactics to better serve patients, secure the right collaborators and partners, and deliver improved health solutions. |